Molecular Partners AG (MOLN)
MOLN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:RevenueFromContractsWithCustomers), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1745114/000174511426000009/0001745114-26-000009-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2025-12-31. Converted from CHF at 0.8384 per USD (today's ECB or Federal Reserve reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | MOLN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Switzerland |
| IPO year | 2021 |
| SEC CIK | 0001745114 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | Switzerland |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$73.5M |
| Operating income | -$69.3M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | -100.0% |
| Cash | $98.6M |
| Total assets | $121.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Reported in CHF; shown in US dollars.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-03-12 |
| Cash and burn | 82.7M CHF cash; operating cash flow -12.8M CHF a quarter. | Report 2025-12-31 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG AG, Zurich, Switzerland | PCAOB Form AP 2026-04-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | 0 CHF | -61.7M CHF | -51.3M CHF | 82.7M CHF | No debt tags | 0 CHF | 20-F 2026-03-12 |
| FY 2024 2024-12-31 | 5.0M CHF | -54.0M CHF | -59.2M CHF | 63.9M CHF | No debt tags | 5.0M CHF | 20-F 2025-03-06 |
| FY 2023 2023-12-31 | 7.0M CHF | -62.0M CHF | -59.0M CHF | 67.3M CHF | No debt tags | 7.0M CHF | 20-F 2025-03-06 |
| FY 2022 2022-12-31 | 189.6M CHF | 117.9M CHF | 118.6M CHF | 87.9M CHF | No debt tags | 189.6M CHF | 20-F 2025-03-06 |
| FY 2021 2021-12-31 | 9.8M CHF | -63.8M CHF | -91.0M CHF | 71.8M CHF | No debt tags | 9.8M CHF | 20-F 2024-03-14 |
| FY 2020 2020-12-31 | 9.3M CHF | -62.8M CHF | -29.0M CHF | 133.7M CHF | No debt tags | 9.3M CHF | 20-F 2023-03-09 |
| FY 2019 2019-12-31 | 20.4M CHF | -36.3M CHF | -1.2M CHF | 75.7M CHF | No debt tags | 20.4M CHF | 20-F 2022-03-15 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in CHF.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | F-3 | 2025-04-11 |
| Latest annual report | 20-F | 2026-03-12 |
| Latest quarterly / interim | 6-K | 2026-10-29 |
Source: SEC EDGAR submissions feed, 121 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -8.6% |
| 1 month | -19.9% |
| 3 months | -30.2% |
| Year to date | -32.6% |
| 1 year | -31.3% |
| From 52-week high | -42.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| VYGR | Voyager Therapeutics Inc. | $1.63 | -5.78% | $101.4M |
| ZURA | Zura Bio Limited | $1.08 | -12.90% | $104.0M |
| OTLK | Outlook Therapeutics Inc. | $0.3960 | -4.12% | $96.4M |
| ARMP | Armata Pharmaceuticals Inc. | $2.99 | -22.74% | $111.2M |
| BDTX | Black Diamond Therapeutics Inc. | $1.53 | +4.08% | $87.9M |
| CMPX | Compass Therapeutics Inc. | $0.6615 | -14.51% | $119.1M |
| LENZ | LENZ Therapeutics Inc. | $3.82 | -7.51% | $120.0M |
| CRDL | Cardiol Therapeutics Inc. Class A Common Shares | $0.9798 | -2.02% | $125.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier